A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment by unknown
A post hoc analysis of dalteparin versus oral anticoagulant (VKA)
therapy for the prevention of recurrent venous thromboembolism
(rVTE) in patients with cancer and renal impairment
Seth Woodruff1 • Guillaume Feuge`re2 • Paula Abreu1 • Joseph Heissler1 •
Marcia T. Ruiz2 • Frank Jen1
Published online: 25 June 2016
 Pfizer 2016. This article is published with open access at Springerlink.com
Abstract Venous thromboembolism (VTE) is a common
and serious complication in patients with cancer; treatment
guidelines recommend extended therapy of C6 months
with low-molecular-weight heparin (LMWH) for treatment
and prevention of recurrent VTE (rVTE) in this population.
This post hoc analysis used data from the CLOT study—a
phase III, randomized, open-label, controlled study
(N = 676)—to compare the efficacy and safety of dal-
teparin, a LMWH, versus vitamin K antagonist (VKA) for
prevention of rVTE in patients with cancer and renal
impairment (creatinine clearance \60 ml/min). Overall,
162/676 (24 %) patients had renal impairment at baseline.
Patients received subcutaneous dalteparin 200 IU/kg once
daily during month 1, followed by 150 IU/kg once daily for
months 2–6; or VKA once daily for 6 months, with initial
overlapping subcutaneous dalteparin 200 IU/kg once daily
for C5 days until international normalized ratio was
2.0–3.0 for 2 consecutive days. Endpoints included the
rates of rVTE (primary) and bleeding events. Overall,
fewer dalteparin-treated patients (2/74 [2.7 %]) experi-
enced C1 adjudicated symptomatic rVTE compared with
VKA-treated patients (15/88 [17.0 %]; hazard ratio = 0.15
[95 % confidence interval 0.03–0.65]; p = 0.01). Bleeding
event rates for both treatments were similar (p = 0.47). In
summary, compared with VKA, dalteparin significantly
reduced risk of rVTE in patients with cancer and renal
impairment (p = 0.01) while exhibiting a comparable
safety profile. This analysis supports dosing patients with
renal impairment in accordance with patients with normal
renal function; however, anti-Xa monitoring could be
considered to further support safety in selected patients,
particularly those with very severe renal impairment.
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Introduction
Patients with cancer experience a higher incidence of
venous thromboembolism (VTE; acute deep vein throm-
bosis [DVT] and/or pulmonary embolism [PE]) than those
without cancer, ranging from 3.8–30.7 % [1], depending on
the cancer site [2–4], stage and grade [5, 6]. The risk of
VTE is partly attributable to the hypercoagulable state
induced by the cancer itself [4], and also can be signifi-
cantly increased by use of cancer interventions such as
chemotherapy, surgery, radiotherapy, hormonal therapy
and other targeted therapies [4, 7–9]. Therefore, patients
with cancer exhibit up to a sixfold higher risk of VTE than
those without cancer, particularly in patients with advanced
disease, hematological malignancies and certain types of
solid tumors, e.g. lung, brain and gastrointestinal tract [4].
Risk of VTE is highest following the cancer diagnosis and
when distant metastasis has occurred [3]. Development of
VTE in patients with cancer is associated with poor prog-
nosis and decreased survival [4, 10].
Standard treatment for VTE in patients with cancer is
long-term anticoagulant therapy [9, 11, 12]. Previously, this
included initial intravenous unfractionated heparin (UFH)
or initial subcutaneous high-dose low-molecular-weight
heparin (LMWH) overlapped and followed by an oral
vitamin K antagonist (VKA) administered for[3 months
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[13]. However, dosing of VKA therapy requires inconve-
nient, close laboratory monitoring [14], and VTE recur-
rence rates in patients with cancer receiving this treatment
regimen are higher than in patients without cancer [15]. Use
of VKAs to treat VTE in patients with cancer also has
proved challenging because of patient nausea, vomiting and
anorexia, drug–drug interactions, poor venous access,
bleeding complications and difficulty in maintaining the
international normalized ratio (INR) within the targeted
therapeutic range [9].
Because of the insufficiencies associated with VKA
treatment, the CLOT study compared 6-month treatment
with dalteparin, a unique LMWH with mean molecular
weight of 6000 daltons, with initial dalteparin overlapped
with and followed by 6 months of VKA for both the acute
treatment and secondary prophylaxis of VTE in patients
diagnosed with cancer and symptomatic proximal DVT and/
or PE [16]. In summary, the results of the study showed a
52 % relative risk reduction of VTE recurrence over
6 months in the dalteparin-only arm comparedwith theVKA
arm (p = 0.002); no significant differences were observed
between groups in the incidence of major or minor bleeding
events. Furthermore, the risk ratio of dalteparin to VKA for
recurrent VTE (rVTE) remained statistically significant in
favor of dalteparin when the model was adjusted for other
factors found to be prognostic for VTE outcome (including
extent and type of tumor). Since the publication of the CLOT
study results, international guidelines have recommended
long-term treatment with high-dose LMWH (C6 months) as
standard care for the acute treatment and secondary pro-
phylaxis of VTE in patients with cancer [9, 11, 17].
Many patients with cancer also suffer from renal impair-
ment, which is clinically relevant because reduced renal
function can cause abnormalities in hemostasis, thereby
increasing the patient’s prothrombotic tendency and bleeding
risk [18]. In a Frenchobservational study of 4684patientswith
varying types of cancer, a majority (57.4 %) of patients had
abnormal creatinine clearance (CrCl; defined as\90 ml/min),
of which 37.6, 18.5 and 1.3 % had a CrCl of 60–89, 30–59 or
\30 ml/min, respectively [19]. Of note, in clinical practice,
the frequency of renal impairment in patients with cancer can
be underestimated if the diagnosis is based on serum crea-
tinine (SrCr) levels [19]. An observational study of patients
with cancer carried out at two French institutions reported that
while 29/316 (9.2 %) patients showed elevated SrCr levels
[20], 23 % of patients with normal SrCr (\110 lmol/l) had a
CrCl of\80 ml/min, with evidence of impaired renal func-
tion. In addition to baseline renal impairment, cancer treat-
ment itself can lead to, or worsen, renal impairment because
such therapies can be nephrotoxic, particularly when used
sequentially or in combination [21].
Reduced renal function also can impact the clinical
outcomes of patients treated with anticoagulants because
renal impairment can limit the elimination of these agents,
potentially leading to bioaccumulation, and therefore, to
adverse bleeding events. Of note, because of different
pharmacokinetic profiles, the risk of bioaccumulation dif-
fers between classes of agents and between agents within
the same class (e.g. LMWHs) [22]. For example, while
UFH is cleared in a dose-dependent manner by the hepatic
reticuloendothelial system, LMWHs primarily undergo
renal elimination [23]. As a result, depending on dose and
duration of treatment, LMWHs, as a class, which include
bemiparin, dalteparin, danaparoid, enoxaparin, nadroparin
and tinzaparin, can accumulate in patients with reduced
renal function more than UFH [14, 22, 23]. However,
LMWHs with higher mean molecular weights (e.g. dal-
teparin or tinzaparin—which was removed from the US
market in 2011) undergo less renal (and more hepatic)
elimination than LMWHs with lower mean molecular
weights (e.g. bemiparin, enoxaparin or nadroparin). As a
result, the risk of bioaccumulation of dalteparin or tinza-
parin in patients with renal impairment is lower than that of
LMWHs with lower mean molecular weights [24, 25].
Standard treatment for VTE in patients with cancer is
long-term therapy with a LMWH. However, many of these
patients have, or will develop, renal impairment, thereby
increasing the risk of anticoagulant bioaccumulation that
could lead to life-threatening adverse bleeding events.
Because the risk of bioaccumulation owing to renal
impairment differs significantly between LMWH agents,
there is a critical need to have prospective published evi-
dence on long-term use of specific LMWHs in patients
with cancer, VTE and renal impairment to help guide
treatment choices. The current analysis aims to address that
gap for dalteparin. The exclusion criterion for the CLOT
trial related to renal function was SrCr level[39 the upper
limit of normal (ULN; 3.6 mg/dl). Consequently, a sig-
nificant number of patients with some degree of renal
impairment, as defined by CrCl, were enrolled in the study.
In this post hoc subanalysis of CLOT, we evaluated the
efficacy and safety of long-term high-dose dalteparin
(therapeutic doses of 150–200 IU/kg/d as opposed to low
prophylactic doses of 2500–5000 IU/d used for primary
VTE prophylaxis) versus VKA in patients with cancer,
VTE and normal/mild (CrCl C 60 ml/min), moderate
(30 B CrCl\ 60 ml/min) or severe (CrCl\ 30 ml/min)
renal impairment at baseline.
Methods
Study design and population
CLOT was an international, multicenter, open-label, ran-
domized clinical trial of 676 patients presenting with
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cancer and VTE. A detailed description of the study design,
population, treatment regimens and outcome measures has
previously been published [16].
Per protocol, patients underwent 6-month treatment with
dalteparin alone, or initial dalteparin overlapped with and
followed by a VKA (i.e. warfarin or acenocoumarol).
Those patients randomly assigned to dalteparin received
once-daily subcutaneous injections of dalteparin 200 IU/kg
(maximum daily dose 18,000 IU) for 1 month, followed by
injections of *150 IU/kg for the remaining 5 months.
Those in the VKA group received once-daily VKA for
6 months, with initial overlapping subcutaneous dalteparin
200 IU/kg once daily for C5 days until INR was 2.0–3.0
for 2 consecutive days. Thereafter, laboratory monitoring
of the INR was performed at each clinical assessment, once
every 2 weeks or more frequently when clinically indi-
cated, to adjust the oral anticoagulant dose. The INR level
in the oral anticoagulant group was measured frequently to
enhance the likelihood that patients were adequately trea-
ted. Using linear interpolation over time, it was estimated
that the INR was in the therapeutic range 46 % of the time,
below the range 30 % of the time, and above the range
24 % of the time.
Dose modification, including temporary interruption of
treatment, was permitted when clinically indicated (i.e. if
patients experienced transient thrombocytopenia or signif-
icant renal impairment: defined as SrCr level[39 ULN).
Full dose was then reinstated once it could be resumed
safely. In patients treated with dalteparin who developed
significant renal impairment, the treatment dose was
adjusted to maintain an anti-Xa therapeutic level of 1 IU/ml
(range 0.5–1.5 IU/ml). If the steady-state anti-Xa level,
measured 4–6 h after the last dalteparin injection, was below
or above the therapeutic range, the dalteparin dose was
altered by switching to the next highest or lowest prefilled
syringe formulation dose, respectively—dalteparin was
supplied as 1 mL single-dose syringes containing 5000,
7500, 10,000, 12,500, 15,000 or 18,000 IU anti-factor
Xa—and the anti-Xa measurement was repeated after 3–4
new doses. This dose adjustment was repeated until the
target anti-Xa therapeutic level was achieved. For those
patients developing significant renal impairment while
receiving VKA, no dose adjustment was made. During
scheduled clinical assessments at baseline, days 7–10 and
months 1, 3 and 6, blood samples were taken for CrCl
measurements, and used to assess changes in renal function
status over the course of the study.
The present post hoc analysis divided patients enrolled
in CLOT into subgroups of those with normal renal func-
tion (CrCl C 60 ml/min), and those with renal impairment
at baseline, (CrCl\ 60 ml/min), calculated using the
Cockcroft–Gault formula [26]. For this analysis, patients
with renal impairment were further classified as having
either moderate (30 B CrCl\ 60 ml/min) or severe renal
impairment (CrCl\ 30 ml/min). Patients with normal
renal function at baseline who developed renal impairment
during the course of CLOT were excluded from this
analysis.
Outcome measures
The primary efficacy outcome was the rate of rVTE (i.e.
the first episode of objectively documented, symptomatic,
recurrent DVT or PE) in the intention-to-treat population.
Secondary safety outcomes included clinically overt
bleeding (any and major) and death in the as-treated pop-
ulation. Diagnostic criteria for rVTE and bleeding events
have been described in detail elsewhere [16]. Briefly, rVTE
was defined by ultrasonography or venography outcomes,
and bleeding event severity was determined by its associ-
ation with death, the site at which it occurred, requirements
for blood transfusion, and impact on hemoglobin level
[16].
Statistical analysis
Baseline demographic and clinical characteristics of
patients with renal impairment at study entry were sum-
marized in frequency tables, with descriptive statistics used
for quantitative variables. VTE recurrence and bleeding
events were summarized by both frequency and proportion.
A two-sided log-rank test was used to compare treatment
effects of dalteparin and VKA on the risk of VTE recur-
rence and bleeding events. Significance was set at the 5 %
level, and hazard ratios (HRs) and 95 % confidence inter-
vals (CIs) were provided. Cox proportional hazard regres-
sion models were used to assess treatment effects on
events.
Descriptive statistics and graphics were used to sum-
marize changes in CrCl from baseline to lowest level




Baseline demographic and clinical characteristics of
patients stratified by renal function and treatment group are
shown in Table 1. Overall, 162/676 (24 %) of patients in
CLOT had renal impairment at baseline (dalteparin arm,
74; VKA arm, 88). Most of these patients had moderate
impairment (dalteparin, 65/74 [88 %]; VKA, 82/88
[93 %]); only a small number of patients had severe renal
impairment (dalteparin, 9/74 [12 %]; VKA, 6/88 [7 %]).
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Patients with renal impairment tended to be older and
female, and weighed less than those with normal renal
function; however, differences in these variables were
anticipated because in addition to SrCr, they were used to
calculate CrCl and therefore to determine patient renal
function. Patients with renal impairment were well mat-
ched for age, body weight, SrCr and CrCl between the two
treatment arms. Most patients had an Eastern Cooperative
Oncology Group status score of 1 or 2, with the distribution
of status scores being comparable among the four sub-
groups. An additional 91 patients in CLOT developed renal
impairment at some point during treatment but were not
included in this analysis.
Dosing and treatment duration
A summary of the average dalteparin dose administered to
patients in each of the three renal function subgroups
during month 1 and months 2–6 is presented in Fig. 1. As
shown, the distributions of the received dalteparin doses
were comparable between renal function subgroups during
months 2–6, with median doses near the dose levels pre-
specified in the protocol and no differences between sub-
groups. Irrespective of renal function at baseline, the
majority ([84 %) of patients received dalteparin at C90 %
of the prescribed levels. During month 1, the mean doses
received by patients with normal renal function, moderate
renal impairment and severe renal impairment were: 190.6,
196.0 and 193.3 IU/kg, respectively; during months 2–6,
the mean doses were 160.3, 157.2 and 159.5 IU/kg,
respectively. Each of these six mean doses was within the
5 % range of the dosages specified in the CLOT study
treatment protocol.
Distribution of dalteparin doses seen in patients with
renal impairment was similar to that for patients with
normal renal function, i.e. there was no systematic reduc-
tion of dalteparin dosage in patients with renal impairment
(including patients with severe impairment). Among the 74
dalteparin-treated patients with renal insufficiency at
baseline, only 1 patient had a temporary dose reduction
owing to increased anti-Xa levels. Similarly, of the 91/676
(13 %) patients in CLOT who developed renal impairment
during the course of the study, 2/91 (2 %) had dose
reductions owing to increased anti-Xa levels.
VTE recurrence
Overall, 2/74 (2.7 %) dalteparin-treated patients with renal
impairment (moderate impairment, 2) and 15/88 (17.0 %)
VKA-treated patients with renal impairment (moderate
impairment, 14; severe impairment, 1) in the intention-to-
treat population, experienced C1 adjudicated symptomatic
rVTE during the 6-month study period (cox proportional
hazard model: HR [95 % CI], 0.15 [0.03–0.65] in favor of
dalteparin; p = 0.01; Table 2). A Kaplan–Meier curve
showing time to first rVTE during the 6-month study per-
iod for patients with renal impairment is presented in Fig. 2
(p value calculated using log-rank test).
Cox proportional hazard models were used to evaluate
the potential influence of baseline renal function on the
Table 1 Baseline characteristics of patients with renal impairment or normal renal function, by treatment









Median (range) age (years) 71.0 (31.7–84.6) 73.9 (38.6–89.3) 61.7 (22.0–80.6) 61.1 (27.9–86.1)
Age\65 years, no. (%) 25 (33.8) 20 (22.7) 157 (59.5) 162 (64.8)
Age C65 years, no. (%) 49 (66.2) 68 (77.3) 107 (40.5) 88 (35.2)
Median (range) weight (kg) 64.0 (39.0–105.0) 65.0 (40.0–104.0) 75.5 (41.0–132.0) 75.0 (45.0–128.0)
Female, no. (%) 48 (64.9) 47 (53.4) 131 (49.6) 122 (48.8)
Median (range) CrCl (ml/min) (no. of patients)
Normala (CrCl C60) NA NA 90.4 (60.0–233.5) [245] 92.5 (60.2–202.7) [225]
Moderate impairment (30 B CrCl\ 60) 48.5 (31.1–59.5) [65] 47.8 (31.5–59.7) [82] NA NA
Severe impairment (CrCl\ 30) 27.6 (22.2–29.4) [9] 26.5 (21.0–29.6) [6] NA NA
Median (range) SrCr (mg/dl) (no. of patients)
Normal (SrCr B1.2) 1.0 (0.6–1.2) [35] 1.0 (0.7–1.2) [45] 0.8 (0.3–1.2) [233] 0.8 (0.4–1.2) [208]
High (SrCr[ 1.2) 1.6 (1.2–3.3) [39] 1.5 (1.2–2.9) [43] 1.3 (1.2–1.4) [12] 1.4 (1.2–2.0) [17]
VKA vitamin K antagonist, CrCl creatinine clearance, SrCr serum creatinine, NA not applicable
a 19 and 25 patients were missing CrCl baseline data in the dalteparin and VKA groups, respectively
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likelihood of VTE recurrence. Specifically, both numerical
CrCl values and a derived indicator variable (based on a
CrCl less than or greater than 60 ml/min) were used as
renal function indices and as possible explanatory variables
in two Cox models calculated with or without prognostic
variables. Prognostic variables included extent of tumor
(nonmetastatic vs. metastatic), type of tumor (gastroin-
testinal vs. breast, lung vs. breast, genitourinary vs. breast,
hematological vs. breast, other vs. breast), current smoking
status (smoker vs. nonsmoker) and age at study entry.
Neither the numerical CrCl value nor the derived indicator
value was found in either Cox model to influence the
treatment effect of dalteparin versus VKA on VTE
recurrence.
Bleeding events
First instances of any bleeding or major bleeding were
determined in the as-treated population according to






































Months 2–6Fig. 1 Summary of average
dalteparin dose (IU/kg) during
month 1 and months 2–6 of
treatment. The shaded box at the
center contains 50 % of the
data; the white bar within
indicates the median. The solid
horizontal lines are drawn at the
prescribed doses, i.e. 200 IU/kg
for month 1 and 150 IU/kg for
months 2–6 of the study. The
dotted lines indicate values at
*90 % of the prescribed levels,
respectively
Table 2 Comparison of treatment effects on first VTE recurrence, first any bleeding and first major bleeding in patients with renal impairment
Variable Treatment Patients at risk (no.) Events % p valuea Hazard ratio (95 % CI)
VTE (n = 162)b Dalteparin 74 2 2.7 0.0111 0.148 (0.034–0.647)
VKA 88 15 17.0
Any bleeding (n = 161)c Dalteparin 74 15 20.3 0.4658 0.781 (0.402–1.517)
VKA 87 21 24.1
Major bleeding (n = 161)c Dalteparin 74 7 9.5 0.6511 1.287 (0.432–3.834)
VKA 87 6 6.9
VTE venous thromboembolism, CI confidence interval, VKA vitamin K antagonist, ITT intention-to-treat, AST as-treated
a Cox proportional model with treatment as covariate
b ITT patients
c AST patients
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Any bleeding
The proportion of patients with renal impairment at base-
line in the as-treated population experiencing C1 bleeding
episode was higher in the VKA treatment arm than in the
dalteparin treatment arm (21/87 [24.1 %] vs. 15/74
[20.3 %]; Table 2); however, the between-group difference
in cumulative probability of any bleeding event was not
statistically significant (p = 0.47).
The rate of any bleeding increased as renal function
declined in both treatment groups (Table 3). Among as-
treated patients with moderate renal impairment, bleeding
events were experienced by 10/65 (15.4 %) of those treated
with dalteparin and 18/81 (22.2 %) of those treated with
VKA. In patients with severe renal impairment, bleeding
events were experienced by 5/9 (55.6 %) of those receiving
dalteparin and 3/6 (50.0 %) of those receiving VKA.
Major bleeding
Dalteparin was associated with a numerically higher inci-
dence of C1 adjudicated major bleeding event compared
with VKA, but the between-group difference in cumulative
probability of such an event was not statistically significant
(p = 0.65; Table 2). Specifically, incidence of a major
bleeding event in as-treated patients with moderate renal
impairment was 5/65 (7.7 %) in patients treated with dal-
teparin and 5/81 (6.2 %) in patients treated with VKA.
Incidence of major bleeding events in as-treated patients
with severe renal impairment was 2/9 (22.2 %) with dal-
teparin and 1/6 (16.7 %) with VKA (Table 3); there were
few major bleeding events seen in patients with moderate
or severe renal impairment in either treatment group.
Death rates
The overall death rate among patients with renal impair-
ment during the 6-month study period was 79/162
(48.8 %). The death rate in dalteparin-treated patients was
36/74 (48.6 %) and was 43/88 (48.9 %) in VKA-treated
patients.
Change in renal function status
Change in renal function status during treatment in the
intention-to-treat population is summarized in Table 4.
Results indicate that 79 % of patients treated with dal-
teparin and 75 % of patients treated with VKA who had
normal renal function at baseline maintained this status
during the treatment period, while 75 % of dalteparin-
treated patients and 79 % of VKA-treated patients with
moderate renal impairment at baseline either maintained or
improved their renal function during the treatment period
(Table 4).
CrCl at baseline and at its lowest point during treatment


















































Patients at risk, n (events)
Fig. 2 Time to first recurrent venous thromboembolism (deep vein thrombosis/pulmonary embolism) during the 6-month study period for
patients with renal impairment. p value calculated using log-rank test. VKA vitamin K antagonist
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Most measured CrCl values were below the line of identity
and the slopes of the regression lines were\1, indicating
that most patients with or without renal impairment at
baseline experienced a decrease in CrCl level during
treatment. However, this change in CrCl was not suffi-
ciently large enough to change the classification of renal
function (e.g. normal, moderate impairment, severe
impairment) assigned to most patients. The regression lines
for dalteparin and VKA were similar, thereby indicating
that change in renal function was comparable between
treatment groups and that stability of renal function over
the course of the study was similar.
Discussion
In this post hoc analysis of prespecified endpoints, patients
with cancer who had both acute VTE and impaired renal
function at baseline demonstrated an 86.5 % relative risk
reduction of developing rVTE when treated with dalteparin
versus VKA. In the dalteparin arm, VTE recurrence event
rates decreased as baseline renal function declined from
normal to moderate or severe (although the number of
patients in the severe group was small), while VTE
recurrence event rates remained stable as renal function
declined in the VKA arm. In both treatment groups, rates of
Table 3 VTE recurrence and bleeding events in the subgroups determined by treatment and renal function at baseline
Treatment Renal functiona VTE Any bleeding Major bleeding
At riskb (no.) Events, no. (%) At riskc (no.) Events, no. (%) At riskc (no.) Events, no. (%)
Dalteparin Missing baseline CrCl 19 3 (15.8) 19 2 (10.5) 19 2 (10.5)
Normal 245 22 (9.0) 245 29 (11.8) 245 10 (4.1)
Renal impairment 74 2 (2.7) 74 15 (20.3) 74 7 (9.5)
Moderate impairment 65 2 (3.1) 65 10 (15.4) 65 5 (7.7)
Severe impairment 9 0 9 5 (55.6) 9 2 (22.2)
VKA Missing baseline CrCl 25 2 (8.0) 24 4 (16.7) 24 1 (4.2)
Normal 225 36 (16.0) 224 37 (16.5) 224 5 (2.2)
Renal impairment 88 15 (17.0) 87 21 (24.1) 87 6 (6.9)
Moderate impairment 82 14 (17.1) 81 18 (22.2) 81 5 (6.2)
Severe impairment 6 1 (16.7) 6 3 (50.0) 6 1 (16.7)
VTE venous thromboembolism, CrCl creatinine clearance, VKA vitamin K antagonist, ITT intention-to-treat, AST as-treated
a Normal: CrCl C 60 ml/min; moderate impairment: 30 B CrCl\ 60 ml/min; severe impairment: CrCl\ 30 ml/min
b ITT population
c AST population, 3 patients less
Table 4 Frequency of renal function change from baseline to worst levels during treatment (ITT population)
Treatment Baseline renal functiona Baseline (no.) Worst renal functiona experienced during treatment, no. (%)
CrCl missing Normal Moderate impairment Severe impairment
Dalteparin (n = 338) CrCl missing 19 1 (5) 13 (68) 4 (21) 1 (5)
Normal 245 10 (4) 193 (79) 40 (16) 2 (1)
Moderate impairment 65 5 (8) 6 (9) 43 (66) 11 (17)
Severe impairment 9 0 0 0 9 (100)
VKA (n = 338) CrCl missing 25 2 (8) 16 (64) 5 (20) 2 (8)
Normal 225 20 (9) 168 (75) 31 (14) 6 (3)
Moderate impairment 82 6 (7) 11 (13) 54 (66) 11 (13)
Severe impairment 6 0 0 1 (17) 5 (83)
ITT intention-to-treat, CrCl creatinine clearance, VKA vitamin K antagonist
a Normal: CrCl C 60 ml/min; moderate impairment: 30 B CrCl\ 60 ml/min; severe impairment: CrCl\ 30 ml/min
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any bleeding were higher in patients with renal impairment
(moderate or severe) than in patients with normal renal
function, respectively (20.3 and 11.8 % for dalteparin; 24.1
and 16.5 % for VKA).
Overall, the post hoc efficacy findings in patients with
moderate and severe renal impairment were consistent with
those described for the full CLOT study population where
dalteparin reduced the cumulative risk of rVTE at
6 months by 52 % versus VKA, without increasing risk of
bleeding [16]. In general, safety findings were similar
between patients with renal impairment and those com-
prising the entire CLOT study population. Namely, there
were no significant differences in rates of any bleeding
event or major bleeding events between dalteparin and
VKA treatment groups [16]. A higher death rate of 49 %
was observed among patients with renal impairment,
compared with 40 % among all patients in CLOT.
Comparable safety findings were recently reported for
dalteparin from the DALTECAN study, a single-arm
12-month safety study modeled after CLOT that also
included patients with renal impairment [27].
Another large randomized trial modeled after CLOT but
evaluating a different LMWH (tinzaparin) versus VKA,
also was recently published [28]. In this study, known as
CATCH, 900 patients with active cancer and VTE were
randomized to tinzaparin 175 IU/kg once daily for
6 months or to tinzaparin 175 IU/kg once daily for
5–10 days followed by warfarin for 6 months [28]. Over-
all, in contrast to CLOT, the results reported no significant
reduction in a composite measure of rVTE, overall mor-
tality or major bleeding events following 6-month treat-
ment with tinzaparin [28]. A subanalysis of CATCH
directly investigated the impact of renal impairment on
rVTE or clinically relevant bleeding (CRB) incidences;
among 129 patients with CrCl\ 60 ml/min, 14 % devel-
oped rVTE and 20 % had CRB. Of 733 patients with
normal renal function, 8 % developed rVTE, while 15 %
had CRB. For those patients with CrCl\ 60 ml/min, no
statistically significant differences were observed in rVTE
and CRB incidences between the tinzaparin and warfarin
treatment arms [29].
This post hoc analysis of CLOT and the subanalysis of
CATCH are the earliest studies reporting long-term 6-month
use of specific LMWHs to treat VTE in patients with active
cancer and renal impairment. These two analyses provide
evidence suggesting that both dalteparin and tinzaparin,
although different agents, have safety profiles similar to
VKA in this indication and patient cohort. In these two
studies, bleeding events were markedly increased when
anticoagulant treatment (LWMHorVKA)was administered
to patients with renal impairment (compared with patients
with normal renal function), but when LMWH treatment was
compared with VKA, there was no evidence of excess
bleeding (as would be expected should bioaccumulation be
occurring). Intriguingly, this post hoc analysis of CLOT
documented a larger and statistically significant reduction in
rVTE with dalteparin in renally impaired patients than was
previously demonstrated in the entire CLOT study



















































































































































































































































































































































































Fig. 3 Lowest creatinine clearance (CrCl) during treatment versus
baseline CrCl in patients given dalteparin (F) or vitamin K antagonist
(VKA [O]; intention-to-treat population). The solid black diagonal
line is the line of identity (y = x). Linear regression lines, i.e. the
solid blue diagonal line for patients receiving VKA and the solid red
diagonal line for those receiving dalteparin, have been added to
indicate trends. The black dashed lines signify CrCl 30 ml/min and
CrCl 60 ml/min
A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy… 501
123
population. The subanalysis of CATCH, however, reported
similar rates of rVTE with tinzaparin and VKA in renally
impaired patients, and these rates are almost twofold higher
than observed in the entire CATCH study population. The
difference in efficacy observed between dalteparin and tin-
zaparin versus VKA in this indication is unexplained and
could be due to chance, or because of differences in phar-
macodynamics that become clinically relevant in the
hypercoagulable state induced by cancer, and/or because of
study design variations.
In terms of dosing, the mean dalteparin dose received by
patients within the three renal subgroups (normal, moderate
impairment, severe impairment) fell within ±5 % of the
range specified in the CLOT study protocol. Specifically,
the protocol defined the month 1 dose to be 200 IU/kg per
day, an amount designed to provide therapeutic levels of
anticoagulation for acute VTE at a time when recurrence
rates are highest in patients with cancer [15]. To reduce
risk of bleeding complications during months 2–6, the dose
was reduced to approximately 75–83 % of the initial daily
dose (i.e. about 150 IU/kg per day), without regard to renal
function and in the absence of serum anti-Xa monitoring.
Dalteparin dose modification or interruption was, however,
permitted if patients experienced transient thrombocy-
topenia or significant renal impairment. Importantly, we
found no systematic or widespread reduction of dalteparin
dosage in patients with renal impairment, even in those
with CrCl\ 30 ml/min. Indeed, elevated anti-Xa levels led
to a reduction in the dose of dalteparin in only 1/74 patients
enrolled with a baseline CrCl\ 60 ml/min.
Of note, not every hospital or clinic has ready access to
anti-Xa monitoring tests. Based on previously published
data, current American Society of Clinical Oncology
guidelines do advise that if anti-Xa monitoring is unavail-
able for patients with moderate to severe renal impairment,
then UFH and VKAs are safer options for initial and long-
term treatment, respectively [17]. Similarly, current
National Comprehensive Cancer Network guidelines,
which highlight that only limited data are available to
support the clinical relevance of anti-Xa monitoring, rec-
ommend generally limiting the use of LMWHs in patients
with renal insufficiency, rather than close monitoring [30].
Some limitations of this exploratory post hoc analysis
are evident. First, patients with SrCr[ 3.6 mg/dl were
excluded from CLOT, thus limiting enrollment of patients
with severe renal insufficiency. Indeed, only 15 patients
enrolled in the two treatment arms had severe renal
impairment (i.e. CrCl\ 30 ml/min). However, the preva-
lence of severe renal insufficiency in patients with cancer
has been shown to be low [19]. Second, CLOT did not
stratify patients by the presence or severity of renal
impairment, nor was it powered to detect between-treat-
ment differences for most subgroups. However, a review of
baseline characteristics of patients with CrCl\ 60 ml/min
demonstrated reasonable comparability between the dal-
teparin and VKA subgroups, thus permitting a statistical
analysis of the treatment effects of dalteparin versus VKA
on efficacy and safety endpoints in this subpopulation.
Despite these limitations, a review of currently available
published literature indicated that CLOT offered the largest
safety and efficacy database of patients with cancer and
renal impairment who were given long-term ([30 days)
VKA and LMWH therapy.
We omitted 91 patients from our statistical analyses who
developed renal impairment during the course of CLOT
because heterogeneity in the cause, duration and course of
renal function in patients who developed renal dysfunction
during the study would have invalidated comparisons
between patients with and without renal impairment. Those
patients who transitioned from normal to impaired renal
status were not a statistically well-defined subpopulation, i.e.
their status was based on an outcome (change in renal
function) that occurred at variable times during treatment.
Moreover, the combined population of patients with renal
impairment—those identified at baseline plus those who
became impaired during treatment—was not truly random-
ized between treatment arms, further making any compar-
isons statistically invalid.
Efficacy and safety data from this post hoc analysis
provide useful information to clinicians considering use of
dalteparin to prevent rVTE in patients with cancer and
renal impairment. However, the results cannot be extrap-
olated to other LMWHs because the pharmacokinetic and
pharmacodynamic profiles of LMWHs clearly differ [31].
This reflects differences in manufacturing processes [32]
and also mean molecular weight [24], which is considered
to determine the extent to which LMWHs undergo renal
elimination [25].
Given the findings of the current analysis, a pharma-
coeconomic analysis is planned to test the hypothesis that
dalteparin may be both cost effective and cost saving when
used in patients with cancer and renal impairment. This
analysis builds on a study by Dranitsaris et al. that used
health care resource data collected during CLOT to conduct
a patient-level economic analysis from a Canadian health
care perspective. The investigators reported that secondary
prophylaxis with dalteparin as an alternative to VKA in
patients with cancer was economically attractive [33].
Conclusions
In this post hoc analysis of patients with active cancer and
acute VTE, high-dose long-term treatment with dalteparin
significantly reduced the risk of rVTE in patients with renal
impairment and had a comparable safety profile versus
502 S. Woodruff et al.
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VKA. These findings, which are specific for dalteparin, are
consistent with results reported previously from both the
full CLOT study [16], which evaluated clinical outcomes
with dalteparin and VKA in a large cohort of patients with
active cancer and VTE who were treated for 6 months, and
DALTECAN, a 12-month safety study [27].
No evidence emerged from this analysis to support
dosing of dalteparin in patients with renal impairment other
than with the dosages recommended in the CLOT study
protocol. Baseline renal impairment leading to elevated
anti-Xa levels was an exceptionally rare reason for dose
reduction during dalteparin treatment. However, bleeding
events were more common in the presence of renal insuf-
ficiency, particularly in patients with severe renal impair-
ment. Therefore, in line with American College of Chest
Physicians recommendations, clinicians who select dal-
teparin for the treatment of VTE in patients with cancer
and renal impairment should continue to consider moni-
toring steady-state anti-Xa levels [22].
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